Cogent’s bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.
Latest Ratings for COGT
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2021 | HC Wainwright & Co. | Maintains | Buy | |
| Oct 2021 | HC Wainwright & Co. | Initiates Coverage On | Buy | |
| Dec 2020 | Piper Sandler | Initiates Coverage On | Overweight |
